LLY•benzinga•
Verve Therapeutics Touts Positive Data From Gene Editing Medicine To Lower Cholesterol After Single Dose
Summary
Verve shares Phase 1b results of VERVE-102, showing dose-dependent LDL-C reductions and strong safety in patients with HeFH or premature CAD.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 14, 2025 by benzinga